Imvax

Imvax is a biotechnology company dedicated to developing novel vaccines and immunotherapies for patients to treat malignant gliomas and other cancers with unmet medical needs. Its product, IGV-001, is an autologous tumor cell vaccine that elicits a multifaceted response against tumor cells by harnessing the patient's immune system as a defense mechanism.